RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA

In this episode of RhAPPcast, Amanda Mixon, PA-C, President of Rheumatology Advanced Practice Providers (RhAPP), is joined by Audrey Gibson, PA-C, a seasoned rheumatology provider with nearly two decades of experience in private practice near Atlanta, Georgia. Together, they explore the latest clinical findings from the Discover trials, discuss the anticipated STAR trial (2025), and highlight how IL-23 inhibition is shaping Psoriatic Arthritis (PsA) treatment.With IL-23 inhibitors offering durable improvements in spinal pain, BASDAI scores, and ASAS responses, this episode focuses on how Guselkumab is addressing axial symptoms and inflammation in PsA patients, especially those with psoriasis and sacroiliitis. The discussion also differentiates Axial PsA from Axial Spondyloarthritis (AxSpA)—two conditions with overlapping but distinct disease mechanisms.As a leader in rheumatology education, Amanda Mixon, PA-C, brings her expertise in clinical practice, education, and advocacy to the conversation, while Audrey Gibson, PA-C, shares real-world clinical insights on IL-23 inhibitors and their role in managing PsA.With the STAR trial set to further evaluate Guselkumab’s effectiveness in AxPsA, this discussion is essential for rheumatology providers looking to refine their treatment strategies and stay ahead of the latest advancements in PsA management.For more expert insights on PsA and IL-23 targeted therapy, visit RhAPP.org or explore the RhAPP ACE App for the latest educational resources.